Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Submucosal Bevacizumab for Recurrent Epistaxis in HHT
NCT01402531Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Jul 2010
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by University of California, San Diego. Primary endpoints: Epistaxis Severity Score at 2 years, Hematocrit at 2 years and 2 more. Started Jul 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT01402531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01402531.